Leukotrienes are biologically active lipid metabolites of arachidonic acid that are involved in inflammation and play a significant role in respiratory and cardiovascular disease. The integral nuclear membrane protein 5-lipoxygenase-activating protein (FLAP) is essential for leukotriene biosynthesis in response to cellular activation. The crystal structures of human FLAP with two inhibitors were recently determined. Inhibitors are bound within the lipid-exposed portion of FLAP, and the unexpected location of the inhibitor-binding site suggests a transport mechanism for arachidonic acid and provides functional insights into leukotriene biosynthesis. This chapter describes how this human integral membrane crystal structure was solved by pushing the limits of low-resolution structure determination and refinement, demonstrating how a low-resolution structure can impact biology and chemistry, and discusses future opportunities for structure-based drug design for this therapeutic target. © 2012 Springer Science+Business Media, LLC.
CITATION STYLE
Ferguson, A. D. (2012). Structure-based drug design on membrane protein targets: Human integral membrane protein 5-lipoxygenase-activating protein. Methods in Molecular Biology, 841, 267–290. https://doi.org/10.1007/978-1-61779-520-6_12
Mendeley helps you to discover research relevant for your work.